<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555178</url>
  </required_header>
  <id_info>
    <org_study_id>18-116 ex 06/07</org_study_id>
    <nct_id>NCT00555178</nct_id>
  </id_info>
  <brief_title>Regulatory T Cells (Tregs) in Polymorphic Light Eruption</brief_title>
  <official_title>Regulatory T Cells (Tregs) in Polymorphic Light Eruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence,&#xD;
      particularly among young women (up to 20%). The disease is characterized through itchy skin&#xD;
      lesions on sun-exposed body sites occurring after sun exposure mostly in spring and early&#xD;
      summer. Its etiopathogenesis is unknown but resistance to UV-induced immunosuppression with&#xD;
      subsequent immune reactions against skin photoneoantigens has been suggested. Regulatory T&#xD;
      cells (CD4+CD25+FoxP3+) (Tregs), a subset of T helper cells, are crucial for the induction of&#xD;
      immunosuppression. We will test the hypothesis that PLE patients show pathogenic fluctuating&#xD;
      Treg levels and function and related parameters over the seasons of the year, possibly being&#xD;
      responsible for lack of immune modulation and autoimmunity in PLE. Natural or medical&#xD;
      photohardening may normalize Treg deficiency in PLE and lead to clinical adaption in summer.&#xD;
      Better insight into the pathogenesis of PLE may give clues to develop new therapeutic&#xD;
      strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PLE patients will be recruited through the Photodermatology Unit of the Department of&#xD;
      Dermatology, Medical University of Graz, Graz, Austria. Eligible patients will be identified&#xD;
      through diagnosis-related computer-assisted search in the electronic patient chart system of&#xD;
      the Unit. The diagnosis of PLE will be verified by patient's history, clinical symptoms,&#xD;
      histologic findings, laboratory studies and/or phototesting procedures.&#xD;
&#xD;
      The levels and function of Tregs, memory T cells, neutrophils, mast cells, Langerhans cells,&#xD;
      cytokine and chemokine profiles, vitamin D levels in the blood and/or skin will be studied in&#xD;
      PLE patients compared to control groups. Volunteers of four groups will be enrolled in this&#xD;
      study: i) patients with PLE undergoing preventive medical UV photohardening in spring; ii)&#xD;
      PLE patients not undergoing preventive UV photohardening; iii) healthy control subjects; and&#xD;
      iv) patients with other diseases (including psoriasis, atopic dermatitis, and other&#xD;
      conditions) undergoing therapeutic phototherapy.&#xD;
&#xD;
      Blood will be taken by venous puncture (mainly of a cubital vein) from the individual study&#xD;
      participants at four defined time points during the year: (i) spring (March to April) (before&#xD;
      medical photohardening in PLE patients); (ii) spring/early summer (April to June)&#xD;
      (immediately after medical photohardening of PLE patients); (iii) late summer (August to&#xD;
      September); and (iv) late fall (November to December). In addition, optional skin biopsies&#xD;
      will be taken to study the parameters listed above. The statistical power analysis (alpha&#xD;
      0.05; power 0.8; assumed difference in Treg level/function of 30% among groups; based on the&#xD;
      data by Myara et al., 2005) revealed that 23 patients (21+2 expected drop-outs) need to be&#xD;
      enrolled per patient group. All patients of the non-PLE groups will be sex- and age&#xD;
      (plus/minus 5 years)-matched to the PLE subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treg level and function</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and/or skin cytokine and chemokine levels, vitamin D status, and other immunoregulatory parameters (see above)</measure>
    <time_frame>prospective</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Polymorphic Light Eruption</condition>
  <condition>Psoriasis</condition>
  <condition>Atopic Eczema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with polymorphic light eruption without medical photohardening treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with polymorphic light eruption treated with medical photohardening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients with other disorders (including psoriasis) treated with phototherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Normal healthy subjects</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic patients and community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  Patients with confirmed PLE diagnosis either by typical anamnesis and/or typical&#xD;
             histology of lesions and/or positive phototesting results (group 1 and 2); healthy&#xD;
             subjects (group 3); patients with phototherapy-responsive disease (including&#xD;
             psoriasis, atopic dermatitis, and other conditions (group 4).&#xD;
&#xD;
          -  Good general health status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of malignant skin tumors&#xD;
&#xD;
          -  Dysplastic melanocytic nevus syndrome&#xD;
&#xD;
          -  Certain photosensitive disorders (including porphyria, chronic actinic dermatitis,&#xD;
             Xeroderma pigmentosum, basal cell nevus syndrome)&#xD;
&#xD;
          -  Autoimmune disease (lupus erythematodes, scleroderma, dermatomyositis)&#xD;
&#xD;
          -  Systemic treatment with steroids and/or other immunosuppressive drugs within the last&#xD;
             6 months&#xD;
&#xD;
          -  Antinuclear antibodies (ds-DNA, Ro, La)&#xD;
&#xD;
          -  First-degree relatives of PLE patients (exclusion criterion for group 3 and 4&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Ongoing or planned specific hyposensitization treatment (i.e. specific immunotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department of Dermatology</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2007</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Peter Wolf, MD</investigator_full_name>
    <investigator_title>Professor of Bioimmunotherapy</investigator_title>
  </responsible_party>
  <keyword>Polymorphic light eruption</keyword>
  <keyword>Regulatory T cells (Tregs)</keyword>
  <keyword>Seasonal fluctuation</keyword>
  <keyword>UV radiation</keyword>
  <keyword>Phototherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Exanthema</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

